GABA-B receptors are class C G protein-coupled receptors that mediate slow inhibitory responses to the endogenous neurotransmitter γ-aminobutyric acid (GABA). Functional receptors are obligate heterodimers comprising GABA-B1 and GABA-B2, encoded by GABBR1 and GABBR2, respectively. GABA-B1 contains the orthosteric ligand-binding site, while GABA-B2 enables efficient cell-surface trafficking and mediates G protein activation. The receptors couple predominantly to Gi/o, inhibiting adenylyl cyclase, suppressing presynaptic voltage-gated calcium channels, and activating postsynaptic potassium channels. They are widely expressed throughout the central nervous system, where they reduce neurotransmitter release and neuronal excitability. The major GABA-B1 splice isoforms, GABA-B1a and GABA-B1b, differ in their targeting, with GABA-B1a-containing receptors preferentially associated with presynaptic functions. Receptor responsiveness and surface stability are regulated by phosphorylation, constitutive trafficking, and accessory proteins, including KCTD family members. Baclofen is an approved GABA-B receptor agonist used orally or intrathecally to treat spasticity. Additional agonists, including arbaclofen and lesogaberan, have undergone clinical testing, while positive allosteric modulators remain investigational.